ACTON, Mass. / Nov 01, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced a series of initiatives in recognition of National Diabetes Awareness Month and World Diabetes Day.
“Our commitment to people with diabetes extends beyond our innovative insulin delivery technology,” said Jim Hollingshead, President and Chief Executive Officer. “World Diabetes Day may be just one day on the calendar, but for those living with diabetes, every day requires resilience and strength. By raising awareness today, we pave the way for a world where care, support, and understanding are accessible to all who need it.”
World Diabetes Day
World Diabetes Day is recognized globally on Tuesday, November 14, and the Insulet team will appear at the Nasdaq Stock Market for the ninth consecutive year by ringing the closing bell at 4:00 p.m. ET. Mr. Hollingshead will be joined by a group of global Insulet employees and customers and will speak about the importance of raising diabetes awareness and Insulet’s mission. The Nasdaq Stock Market closing bell ceremony will be aired live on the Nasdaq website and broadcast on CNBC and MSNBC TV.
Earlier that day, Insulet employees will join the American Association of Nurse Practitioners (AANP) at NBC’s TODAY Show, to recognize Nurse Practitioner Week and the important role nurse practitioners play in diabetes management. The intersection of World Diabetes Day and Nurse Practitioner Week provides the perfect opportunity to highlight Insulet employees who are also professionally trained and certified as nurse practitioners.
Diabetes Awareness Month Activities
Orli Adamski is a 16-year-old from New York who has been advocating for people with diabetes since she was diagnosed at age seven. Ms. Adamski will join the Insulet team at the Nasdaq closing bell ceremony, representing the Podder community, just as she did last summer as a delegate to JDRF’s 2023 Children’s Congress.
“There are no breaks with type 1 diabetes,” said Ms. Adamski. “It impacts every single moment of my life, and so many other lives. It’s important to create awareness of the challenges that people with diabetes face, including gaining access to technology like Omnipod 5.”
In order to better serve Insulet’s customers, the Company is also planning various employee events and activities to increase awareness of diabetes.
To learn more about diabetes or to access helpful resources for living with diabetes, visit the American Diabetes Association, JDRF, and the International Diabetes Federation.
About Insulet Corporation
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections and zero fingersticks. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.
©2023 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.
Last Trade: | US$260.12 |
Daily Change: | -1.04 -0.40 |
Daily Volume: | 916,463 |
Market Cap: | US$18.240B |
November 07, 2024 August 26, 2024 August 20, 2024 August 14, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB